BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25837271)

  • 1. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
    Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
    Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
    Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
    Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation.
    Xin Y; Yin F; Qi S; Shen L; Xu Y; Luo L; Lan L; Yin Z
    Toxicol Lett; 2013 Aug; 221(2):73-82. PubMed ID: 23792430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
    Wang Z; Yang L; Xia Y; Guo C; Kong L
    Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
    Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
    Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
    Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
    Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line.
    Wang Z; Xia Q; Cui J; Diao Y; Li J
    Oncol Rep; 2014 Jun; 31(6):2720-6. PubMed ID: 24788927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.
    Choi BH; Kim CG; Lim Y; Shin SY; Lee YH
    Cancer Lett; 2008 Jan; 259(1):111-8. PubMed ID: 18006147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
    Abdin SM; Tolba MF; Zaher DM; Omar HA
    Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling.
    Lu Y; Li F; Xu T; Sun J
    Int J Mol Med; 2017 Apr; 39(4):993-1000. PubMed ID: 28260091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
    Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
    Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
    Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
    Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
    Wang S; Wang L; Chen M; Wang Y
    Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.